Cannabidiol and Cannabigerol, Nonpsychotropic Cannabinoids, as Analgesics that Effectively Manage Bone Fracture Pain and Promote Healing in Mice

© 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)..

Bone fractures are among the most prevalent musculoskeletal injuries, and pain management is an essential part of fracture treatment. Fractures heal through an early inflammatory phase, followed by repair and remodeling. Nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended for fracture pain control as they potently inhibit the inflammatory phase and, thus, impair the healing. Opioids do not provide a better alternative for several reasons, including abuse potential. Accordingly, there is an unmet clinical need for analgesics that effectively ameliorate postfracture pain without impeding the healing. Here, we investigated the analgesic efficacy of two nonpsychotropic cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), in a mouse model for tibial fracture. Mice with fractured tibiae exhibited increased sensitivity to mechanical, cold, and hot stimuli. Both CBD and CBG normalized pain sensitivity to all tested stimuli, and their analgesic effects were comparable to those of the NSAIDs. Interestingly, CBD and CBG promoted bone healing via multiple mechanisms during the early and late phases. During the early inflammatory phase, both cannabinoids increased the abundance of periosteal bone progenitors in the healing hematoma and promoted the osteogenic commitment of these progenitors. During the later phases of healing, CBD and CBG accelerated the fibrocartilaginous callus mineralization and enhanced the viability and proliferation of bone and bone-marrow cells. These effects culminated in higher bone volume fraction, higher bone mineral density, and improved mechanical quality of the newly formed bone. Together, our data suggest CBD and CBG as therapeutic agents that can replace NSAIDs in managing postfracture pain as both cannabinoids exert potent analgesic effects and, at the same time, promote bone healing. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Errataetall:

CommentIn: J Bone Miner Res. 2023 Nov;38(11):1547-1548. - PMID 37975545

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:38

Enthalten in:

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - 38(2023), 11 vom: 04. Nov., Seite 1560-1576

Sprache:

Englisch

Beteiligte Personen:

Khajuria, Deepak Kumar [VerfasserIn]
Karuppagounder, Vengadeshprabhu [VerfasserIn]
Nowak, Irena [VerfasserIn]
Sepulveda, Diana E [VerfasserIn]
Lewis, Gregory S [VerfasserIn]
Norbury, Christopher C [VerfasserIn]
Raup-Konsavage, Wesley M [VerfasserIn]
Vrana, Kent E [VerfasserIn]
Kamal, Fadia [VerfasserIn]
Elbarbary, Reyad A [VerfasserIn]

Links:

Volltext

Themen:

19GBJ60SN5
ANALGESIC
Anti-Inflammatory Agents, Non-Steroidal
BONE REGENERATION
CANNABIDIOL
CANNABIGEROL
Cannabidiol
Cannabigerol
Cannabinoids
FRACTURE HEALING
J1K406072N
Journal Article
Minerals
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 04.12.2023

Date Revised 11.04.2024

published: Print-Electronic

CommentIn: J Bone Miner Res. 2023 Nov;38(11):1547-1548. - PMID 37975545

Citation Status MEDLINE

doi:

10.1002/jbmr.4902

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM360959288